Naeem A, Elbakkouri K, Alfaiz A, et al.  Antigenic drift of hemagglutinin and neuraminidase in seasonal H1N1 influenza viruses from Saudi Arabia in 2014 to 2015.  J Med Virol.  2020;1--12.  10.1002/jmv.25759 31502247

A

:   alanine

ARIs

:   acute respiratory infections

D

:   aspartic acid

E

:   glutamic acid

H

:   histidine

HA

:   hemagglutinin

HAI Ab

:   hemagglutination inhibition antibodies

I

:   isoleucine

IRB

:   Institutional Review Board

K

:   lysine

KFMC

:   King Fahad Medical City

N

:   asparagine

NA

:   neuraminidase

pdm09

:   pandemic strain of 2009

Q

:   glutamine

RT‐PCR

:   reverse transcription‐polymerase chain reaction

S

:   serine

T

:   threonine

Y

:   tyrosine

1.  INTRODUCTION {#jmv25759-sec-0020}
===============

Influenza is an acute respiratory disease that occurs mostly during the winter season in temperate climates and throughout the year in the tropics.[^1^](#jmv25759-bib-0001){ref-type="ref"} Influenza A and B viruses are the major causes of influenza outbreaks.[^2^](#jmv25759-bib-0002){ref-type="ref"} Two to three different strains of influenza virus circulate during each influenza season.  More than 1 billion cases of influenza occur globally every year, resulting in 3 to 5 million cases of severe illness and 300 000 to 500 000 deaths.  The disease burden and epidemiologic pattern of influenza is due to the changing nature of the antigenic properties of influenza viruses.[^3^](#jmv25759-bib-0003){ref-type="ref"}

Influenza A virus undergoes periodic modifications in the antigenic properties of its envelope glycoproteins; the hemagglutinin (HA) and the neuraminidase (NA).  Three major hemagglutinin subtypes (H1, H2, and H3) and two neuraminidase subtypes (N1 and N2) have evolved to human species subtypes of influenza A virus.[^4^](#jmv25759-bib-0004){ref-type="ref"} Influenza virus genome have eight RNA segments and rate of reassortment among co‐infecting viruses can be high.[^5^](#jmv25759-bib-0005){ref-type="ref"}, [^6^](#jmv25759-bib-0006){ref-type="ref"} Antigenic shift leads to the emergence of new strains by reassortment between animal and human influenza viruses.  The pandemics of 1908, 1957, 1968, and 2009 were caused by new viruses emerging as a result of antigenic shift.[^7^](#jmv25759-bib-0007){ref-type="ref"}, [^8^](#jmv25759-bib-0008){ref-type="ref"} Point mutations in the RNA segments coding for HA or NA are called antigenic drift.  Antigenic drift causes less extensive and severe outbreaks.  Between the years of antigenic shift, the variable extent and severity of influenza outbreaks is due to antigenic drift.[^9^](#jmv25759-bib-0009){ref-type="ref"}

During World War I, Spanish flu pandemic killed 25 to 50 million people between 1918 and 1919 worldwide.[^10^](#jmv25759-bib-0010){ref-type="ref"} Spanish flu was one of the worst epidemics in the history of mankind killing healthy adults between 15 and 34 years.[^11^](#jmv25759-bib-0011){ref-type="ref"} The emergence of an antigenic shift in both hemagglutinin (H1) and neuraminidase (N1) proteins of the influenza A virus had extremely severe consequences.[^12^](#jmv25759-bib-0012){ref-type="ref"} The pathogenicity of the 1918 pandemic influenza virus was first demonstrated in a mouse model using reverse genetics.  After infection in mice, the 1918 pandemic strain replicated efficiently producing 39 000 times more virus copies in the lungs compared to other H1N1 strains.[^13^](#jmv25759-bib-0013){ref-type="ref"} Since 1918, several influenza A virus pandemics have occurred.  Genetic reassortment led to the emergence of the H2N2/1957 and H3N2/1968 pandemic influenza viruses.  In 1957, the antigenic shift in the influenza A strain to H2 and N2 resulted in a severe pandemic causing approximately 1 million deaths worldwide.[^14^](#jmv25759-bib-0014){ref-type="ref"} The 1968 pandemic was less extensive due to an antigenic shift only in hemagglutinin gene (from H2N2 to H3N2).[^15^](#jmv25759-bib-0015){ref-type="ref"} The most recent emergence of the H1N1 influenza virus was in March 2009 in Mexico; however, the pandemic H1N1 virus circulation has continued globally ever since. 

In June 2009, the pandemic alert level (phase 6) was declared by the World Health Organization (WHO).  More than 214 countries reported the confirmed cases of pandemic H1N1 influenza A virus.[^16^](#jmv25759-bib-0016){ref-type="ref"} Influenza A (H1N1) 2009 pandemic strain represented a quadruple, genetic reassortment of two swine strains, a human strain, and an avian strain of influenza A viruses.[^7^](#jmv25759-bib-0007){ref-type="ref"} Centers for Disease Control and Prevention (CDC), USA reported approximately 61 million cases of pandemic H1N1 influenza between April 2009 and 10 April 2010, resulting in 274 000 hospitalizations and 12 470 deaths.[^17^](#jmv25759-bib-0017){ref-type="ref"} The 2009 H1N1 influenza pandemic was also associated with 100 000 to 400 000 deaths due to respiratory infection and 46 000 to 180 000 deaths due to cardiovascular infections.[^18^](#jmv25759-bib-0018){ref-type="ref"}, [^19^](#jmv25759-bib-0019){ref-type="ref"} The disease burden due to pandemic influenza A infection in the USA was 0.12 deaths per 100 000 individuals.[^20^](#jmv25759-bib-0020){ref-type="ref"} Severe pneumonia and acute respiratory distress syndrome caused most of the deaths.[^21^](#jmv25759-bib-0021){ref-type="ref"}

The epidemiology of influenza A (H1N1) pdm09 with a molecular and phylogenetic analysis of HA gene during 2013/2014 influenza season in Canada,[^22^](#jmv25759-bib-0022){ref-type="ref"} 2015/2016 season in Denmark,[^23^](#jmv25759-bib-0023){ref-type="ref"} 2010 to 2014 in Dalian,[^24^](#jmv25759-bib-0024){ref-type="ref"} China,[^25^](#jmv25759-bib-0025){ref-type="ref"} Africa,[^26^](#jmv25759-bib-0026){ref-type="ref"} Europe,[^27^](#jmv25759-bib-0027){ref-type="ref"}, [^28^](#jmv25759-bib-0028){ref-type="ref"} India[^29^](#jmv25759-bib-0029){ref-type="ref"} confirmed the close match of the majority of circulating strains with the vaccine strains.  The majority of influenza A (H1N1) pdm09 circulating in 2015/2016 belonged to the new genetic subgroup subclade 6B.[^23^](#jmv25759-bib-0023){ref-type="ref"}, [^25^](#jmv25759-bib-0025){ref-type="ref"} However, it also revealed a trend of strains to accumulate amino acid variations as a result of multiple re‐introductions and form new phylogenetic groups.  Furthermore, a high number of the strains possessed the amino acid changes D97N (aspartic acid to asparagine), S185T (serine to threonine), K163Q (lysine to glutamine), A256T (alanine to threonine), and K283E (lysine to glutamic acid).[^24^](#jmv25759-bib-0024){ref-type="ref"} Influenza A (H1N1) 2009 pandemic viruses were initially reported in Saudi Arabia with the clinical features of the patients in 2010 from Saudi Arabia; the virus infection was confirmed by reverse transcription‐polymerase chain reaction (RT‐PCR).[^30^](#jmv25759-bib-0030){ref-type="ref"}, [^31^](#jmv25759-bib-0031){ref-type="ref"} Subsequent years have seen the studies reporting genetic diversity, phylogenetic relationships, and amino acid variations of HA and NA genes for influenza from the western region of Saudi Arabia.[^32^](#jmv25759-bib-0032){ref-type="ref"}, [^33^](#jmv25759-bib-0033){ref-type="ref"}

Antigenic drift leads to the emergence of novel strains with a capacity to replicate efficiently in humans after infection or vaccination.  Since a close antigenic match is required between circulating and vaccine strains for the efficacy of vaccines, and the disease burden is increased due to mismatches, therefore it is important to identify the mutations that affect the antibody response against natural infection or vaccination.[^34^](#jmv25759-bib-0034){ref-type="ref"} Especially the antigenic sites of HA and NA, which affect the receptor binding properties[^35^](#jmv25759-bib-0035){ref-type="ref"} and virulence[^36^](#jmv25759-bib-0036){ref-type="ref"} are crucial for understanding antigenic drift. 

The current epidemiological and virological data on circulating influenza viruses in Saudi Arabia are quite deficient, and there is no influenza surveillance program in the country as well.[^37^](#jmv25759-bib-0037){ref-type="ref"} Most of the published work on H1N1 virus in Saudi Arabia deals with specimens originating in the western region during the 2009 influenza pandemic[^33^](#jmv25759-bib-0033){ref-type="ref"}, [^37^](#jmv25759-bib-0037){ref-type="ref"}, [^39^](#jmv25759-bib-0039){ref-type="ref"} and prevalence of different respiratory viruses including H1N1[^38^](#jmv25759-bib-0038){ref-type="ref"}, [^40^](#jmv25759-bib-0040){ref-type="ref"} or surveillance studies involving the pilgrims.[^41^](#jmv25759-bib-0041){ref-type="ref"}, [^44^](#jmv25759-bib-0044){ref-type="ref"} It is important to provide virological, molecular, and epidemiological information on circulating influenza strains, and its associated morbidity and mortality to make informed decisions and to undertake effective control measures to decrease the disease burden.  Following the years of the pandemic, the virus undergoes antigenic drift and there is little published data about this phenomenon in Saudi Arabia.  Therefore, we aimed to identify the circulation patterns, genetic diversity, structural and epidemiological characteristics of influenza A (H1N1) virus in Riyadh, Saudi Arabia from the flu season (2014‐2015). 

2.  MATERIAL AND METHODS {#jmv25759-sec-0030}
=======================

2.1.  Ethical considerations {#jmv25759-sec-0040}
---------------------------

The institutional review board at King Fahad Medical City reviewed and approved the study protocol (IRB register number 16‐266). 

2.2.  Biosafety considerations {#jmv25759-sec-0050}
-----------------------------

The handling of respiratory samples, as well as preparation of aliquots and viral RNA extraction, was executed using appropriate personal protective equipment in the biosafety level two‐laboratory (Research Laboratories, Research Center, King Fahad Medical City, Riyadh, Saudi Arabia). 

2.3.  Study specimens {#jmv25759-sec-0060}
--------------------

The study specimens were obtained from a population (n = 148) admitted to King Fahad Medical City in Riyadh, Saudi Arabia.  All samples testing positive for influenza (H1N1) virus locally by real‐time reverse transcription PCR (rRT‐PCR) assay and admitted to the hospital during 1 September 2014 to 16 December 2015 were used for this study.  Written informed consents were obtained from the patients at the time of admission. 

2.4.  Laboratory investigations {#jmv25759-sec-0070}
------------------------------

Nasopharyngeal swabs and/or aspirates specimens were collected for laboratory‐based investigations.  Demographic information, medical history, and outcome information were collected.  Respiratory specimens were used for influenza H1N1 initial screening and further molecular testing. 

### 2.4.1.  RNA extraction and amplification {#jmv25759-sec-0080}

Total RNA was extracted using QIAamp Viral RNA Mini Kit (Qiagen, MA).  Swabs were dissolved in the lysis buffer.  Eight RNA segments of influenza A virus were simultaneously reverse‐transcribed (RT) and amplified by PCR using SuperScript III One Step RT‐PCR System (Life Technologies, CA) with the primer pairs as described previously[^7^](#jmv25759-bib-0007){ref-type="ref"}.  RT‐PCR products were purified by ExoSAP‐IT Express PCR Product Cleanup Reagent (Applied Biosystems, Foster City, CA).  High‐sensitivity microvolume nucleic acid quantitation was performed using the NanoDrop 3300 Fluorospectrometer.[^45^](#jmv25759-bib-0045){ref-type="ref"}

### 2.4.2.  Genetic sequencing and phylogenetic analyses {#jmv25759-sec-0090}

The nucleotide sequences of the amplified HA and NA fragments from 80 isolates with high copy numbers were determined using M13, sequencing primers and BigDye Terminator v3.1 Cycle Sequence kit according to the manufacturer\'s instructions (Applied Biosystems, San Diego).  Removal of unincorporated ddNTP\'s (Dideoxynucleotides triphosphates), salts and dye blobs was performed with BigDye XTerminator Purification (Applied Biosystems).  Capillary electrophoresis was performed in SeqStudio Sanger Sequencer (Applied Biosystems) and analysis of Sanger Sequencing data by assembly and editing was conducted by Sequencher 5.4.6 (Gene codes corporation, Ann Arbor, MI).  Nucleotide sequences except primer regions were aligned with those retrieved from the Genbank Nucleotide Sequence Database.  Inspection and manual modification and evolutionary analyses were conducted in Molecular Evolutionary Genetics Analysis Version X (MEGA X).  Phylogenies were estimated using maximum likelihood methods implemented in MEGA, version X.[^29^](#jmv25759-bib-0029){ref-type="ref"} The maximum likelihood used Hasegawa‐Kishino‐Yano (HKY) model of nucleotide substitution with γ‐distributed rate variation (HKY + G) and bootstrapping (1000 replicates).  The genomic data were analyzed and submitted to the public database (GenBank: <https://www.ncbi.nlm.nih.gov/genbank>) for HA under accession number (MK246015‐MK246094) and NA under accession number (MK228889‐MK228968). 

### 2.4.3.  Measurement of selection pressure {#jmv25759-sec-0100}

The selective pressure on encoding HA of influenza A(H1N1) was examined by calculating the ratio of synonymous and non‐synonymous substitutions (d*N*/d*S*, defined as *ω*) across lineage on a codon‐by‐codon basis.  The individual site‐specific selection pressure and *ω* were estimated using the single likelihood ancestor counting (SLAC) and fixed effects likelihood (FEL) methods contained in the HYPHY package.[^46^](#jmv25759-bib-0046){ref-type="ref"} All analyses utilized the Datamonkey online tool (<http://www.datamonkey.org>).  The value of ω was estimated based on the neighbor‐joining trees under the GTR substitution model.  The significance level for a positively selected site by either SLAC/FEL or both methods was accepted at 0.1. 

### 2.4.4.  Prediction of glycosylation sites {#jmv25759-sec-0110}

The NetNGlyc 1.0 server was used to predict potential N‐linked glycosylation sites (amino acids Asn‐X‐Ser/Thr, whereby X is any amino acid except Asp or Pro).[^47^](#jmv25759-bib-0047){ref-type="ref"} A threshold value of \>0.5 for the average potential score suggests glycosylation. 

3.  RESULTS {#jmv25759-sec-0120}
==========

The evolutionary relationships between the vaccine and contemporary Saudi H1N1 strains were investigated to better understand what might have caused the surge in influenza cases in 2014/2015 season.  We characterized the complete sequences of 80 isolates for HA and NA genes to understand their relationships from the topologies and structural homology. 

To assess the evolution of the influenza A (H1N1) during the same period, representative circulating local strains from 2010 to 2015 seasons were also compared to the vaccine and reference sequences (Figure [1](#jmv25759-fig-0001){ref-type="fig"}).  There were distinct phylogenetic groups of A (H1N1)pdm09 strains between 2014 and 2015.  All the influenza A (H1N1)pdm09 strains belonged to clade 6 viruses, where 92% (N = 73) grouped into sub‐clade 6b.1 and 8% (N = 7) grouped into clade 6b.2.  Although both sub‐clades were related to the A/California/07/2009 vaccine strain (recommended every year since 2010‐2017) and shared \>98.2% nucleotide and \>97.4% amino acid sequence homology, they were considerably different from A/California/07/2009 in that they had several substitutions (Tables [1](#jmv25759-tbl-0001){ref-type="table"} and  [2](#jmv25759-tbl-0002){ref-type="table"}). 

![ Phylogenetic analysis of influenza A H1N1 HA and NA genes.  The analysis involved 152 nucleotide sequences with a total of 1701 and 1410 positions for HA and NA, respectively.  Sequences from 80 strains isolated in Saudi Arabia from 2014 to 2015 compared to the reference strains of known clades and previously reported strains from Saudi Arabia.  The trees were generated using maximum likelihood by HKY+G model.  Bootstrap values of 1000 replicates \>70 are indicated at the nodes.  The 2014 and 2015 isolates from Saudi Arabia characterized in this study are marked with closed circles, and representative sequences for all the known clades are marked with colored circles.  Reference vaccine strain ((A/Michigan/45/2015) is marked with closed triangle.  Only significant and signature amino acid substitutions are depicted on the tree.  Substitutions shown in red color represent reversions.  Scale bar represents approximately 0.2% nucleotide difference between close relatives](JMV-9999-na-g001){#jmv25759-fig-0001}

###### 

Mutations present in the HA protein of 2014 to 2015 circulating Saudi H1N1 strains compared to the vaccine strain

  -----------------------------------
  ![]( JMV-9999-na-g003.jpg "image")
  -----------------------------------

*Note*: Amino acid substitutions found in the HA protein of circulating H1N1 viruses compared to the HA proteins of A/Michigan/45/2015 and A/California/07/2009.  All mutations are numbered by their position along the amino acid sequence relative to the methionine codon at the beginning of the N‐terminal signal peptide (position 1).  Location of mutations with respect to head domain, stalk domain, and known Ab‐binding sites is indicated.  Green colors indicate isolates with amino acid substitutions in Ab binding site, residues 180 in the Sa antigenic site; 200 and 202 in the Sb antigenic site. 

John Wiley & Sons, Ltd.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response.  It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. 

###### 

Mutations present in the NA protein of 2014 to 2015 circulating Saudi H1N1 strains compared to the vaccine strain

  -----------------------------------
  ![]( JMV-9999-na-g004.jpg "image")
  -----------------------------------

*Note*: Amino acid substitutions found in the NA protein of circulating H1N1 viruses compared to the NA proteins of A/Michigan/45/2015 and A/California/07/2009.  All mutations are numbered by their position along the amino acid sequence relative to the methionine codon at the beginning of the N‐terminal signal peptide (position 1).  The location of mutations with respect to known Ab‐binding sites is indicated.  Gray color indicates mutations in known Ab‐binding sites.  Green color indicates strains with no changes in the Ab‐binding sites. 

John Wiley & Sons, Ltd.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response.  It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. 

Influenza A H1N1 pdm09 viruses were classified into eight major clades in which clade 6 is further sub‐classified into 6A, 6B, 6C, 6B.1, and 6B.2 based on HA gene diversity.  All the isolates had hemagglutinin (HA) gene corresponding to clade 6B (monophyletic) represented by global circulating strains of H1N1pdm09 (Figure [1](#jmv25759-fig-0001){ref-type="fig"}) defined by four major reversions A13T, S101N, S179N, and I223T. The WHO updated the H1N1 strain component of the flu vaccine in 2017 to 2018 season from A/Cal/07/09 to A/Michigan/45/2015.[^44^](#jmv25759-bib-0044){ref-type="ref"} Interestingly, the HA and NA proteins encoded by this strain do not contain all of the mutations found in the majority of 2014 to ‐2015 isolates described in this study. 

The influenza A(H1N1)pdm09 sequences were characterized in a maximum likelihood phylogenetic tree with reference strains rooted from the previous vaccine strain, A/California/07/2009 (Figure [1](#jmv25759-fig-0001){ref-type="fig"}).  The influenza A(H1N1)pdm09 HA sequences characterized from the 2014 to 2015 season exhibited an overall protein homology of 98.5% to 99.5% (average 99.0%) compared to the 2017 to 2018 influenza vaccine component, A/Michigan/45/2015 virus.  All influenza A(H1N1)pdm09 HA sequences contained mutations consistent with the dominating subgroup referred to as clade 6B and could all be further classified as subclade 6B.1 and 6B.2. 

Saudi isolates were found to be clustering more closely to new vaccine strain (Michigan/45/2015) used for 2018/2019 season than the previously used vaccine strain (California/07/2009).  Saudi isolates reported from 2013 clustered into clade 6c (Figure [1](#jmv25759-fig-0001){ref-type="fig"}).  Almost 92% of Saudi viruses from our study formed a subclass branch with high bootstrap value (91/100) designated as 6B.1[^48^](#jmv25759-bib-0048){ref-type="ref"} mainly defined by S179N and I223T reversions.  The remaining seven strains formed another cluster (96/100 bootstrap value) with an S101N, T169V, S179N, I190V, I223T, and G508E amino acid substitutions (designated as sub‐clade 6B.2 in Figure [1](#jmv25759-fig-0001){ref-type="fig"}). 

HA protein surface structure is changed due to the gain or loss of N‐linked glycosylation sites.  This gain can cause modulation of viral antigenicity by the masking effect on important antibody recognition sites.[^49^](#jmv25759-bib-0049){ref-type="ref"} Among the influenza A(H1N1)pdm09 HA sequences characterized in our study (Figure [2](#jmv25759-fig-0002){ref-type="fig"}), one mutation, S179N (serine to asparagine), was observed that caused a predicted gain of a glycosylation motif.[^50^](#jmv25759-bib-0050){ref-type="ref"} Influenza viruses present in nasal and throat swabs from subjects infected during the 2014 to 2015 season encoded 42 amino acid changes in the HA protein compared to the strain A/Michigan/45/2015 (vaccine strain from 2017 to 2018) (Table [1](#jmv25759-tbl-0001){ref-type="table"}).  For H1N1 viruses from our study, the amino acid substitutions or mismatches were only considered if they occurred in five canonical H1N1 HA antigenic sites (Sa, Sb, Ca1, Ca2, Cb) composed of amino acid regions (H1N1 numbering): Sa: 141‐142, 170‐174, 176‐181; Sb: 201‐212; Ca1: 183‐187, 220‐222, 252‐254; Ca2: 154‐159, 238‐239; Cb: 87‐92.[^51^](#jmv25759-bib-0051){ref-type="ref"} Out of the 42 mutations, 7 substitution sites were located in the HA head domain while only 2 sites were located in the stalk domain (Table [1](#jmv25759-tbl-0001){ref-type="table"}).  Four mutations were found in previously characterized[^52^](#jmv25759-bib-0052){ref-type="ref"} Ab‐binding sites. 

![ Amino acid changes present in the HA proteins of 2014 to 2015 circulating H1N1 strains compared to the vaccine strain.  Three‐dimensional models of the A/Cal/04/09 HA1 (single chain) protein (PDB ID: 3LZG), showing the amino acid changes in circulating H1N1 viruses compared to that of the vaccine strain.  Front and backside views of the HA1 monomer protein are shown.  A, The HA antigenic sites Sa (dark blue), Sb (yellow), Ca1 (light pink), Ca2 (dark purple), and Cb (light red) are indicated.  B, S179N amino acid change present in the antigenic site Sa of HA1 of H1N1 circulating strains compared to that of the H1N1 vaccine strain is shown in ribbon in red.  C, The approximate location of HA amino acid change S220T, situated in the Ca1 antigenic site at the subunit interface, is indicated. ( D) top view of head region of HA1 is showing the antigenic sites along with glycosylation site.  The 3D model was customized using PyMOL](JMV-9999-na-g002){#jmv25759-fig-0002}

The circulating strains belonged to subclade 6B.1, defined by HA amino acid substitutions S101N, S179N, and I233T. The majority of the 2014/15 season Saudi isolates formed part of a large cluster possessing an S101N substitution in HA.  Most of these isolates contained S179N (on the Sa antigenic site of HA resulting in a potential glycosylation site) and I233T amino acid substitutions in addition to the S101N substitution and formed a subclade subsequently designated as 6B.1.[^48^](#jmv25759-bib-0048){ref-type="ref"}

As for the NA protein (sequenced from 80 nasopharyngeal aspirates and swabs), 14 amino acid changes were found when compared to the vaccine strain (Table [2](#jmv25759-tbl-0002){ref-type="table"}).  Five out of the fourteen changes (N200S, N248D, I321V, N369K, and K432E) were at previously characterized Ab‐binding sites.[^53^](#jmv25759-bib-0053){ref-type="ref"} Three of the mutations (K432E along the 430 loop, V241I, and N248D) were located near the catalytic site.  All strains encoded the same NA sequence, with the exception of MK228966 (A/Saudi Arabia/143/2014) and MK228893 (A/Saudi Arabia/10/2015) viruses, which did not have the mutations N248D and K432E respectively.  Altogether, these data indicate genetic variability in both, the HA and NA proteins of circulating H1N1 viruses from 2014 to 2015, compared to the vaccine strain. 

Most antibodies elicited by influenza virus by natural infection and vaccination target the globular head domain of HA1, which is distal from the virus surface and readily accessible for immune recognition.  Influenza virus HA, in turn, mutates to escape from pre‐existing immunity.  This mutation‐based immune evasion process is known as antigenic drift.  Early studies proposed five major antigenic sites in the HA1 globular head domain for H1, namely Sa, Sb, Ca1, Ca2, and Cb for H1 HA.[^51^](#jmv25759-bib-0051){ref-type="ref"} The locations of Sa, Sb, and Ca2 of H1 HA partially overlap with the RBS, whereas Ca1 and Cb of H1 HA are more distant from the RBS.  These antigenic sites provide a structural framework to understand the evolutionary dynamics and constraints of the influenza virus in response to humoral immunity.[^54^](#jmv25759-bib-0054){ref-type="ref"} As shown on a 3D model of the HA protein (RCSB PDB ID: 3LZG),[^55^](#jmv25759-bib-0055){ref-type="ref"} five mutations were found in previously characterized[^48^](#jmv25759-bib-0048){ref-type="ref"} Ab‐binding sites: S179N and T180Q, in Sa; P200S and S202T, in Sb; and S220T, in Ca1 (Figure [2C](#jmv25759-fig-0002){ref-type="fig"} and Table [1](#jmv25759-tbl-0001){ref-type="table"}).[^56^](#jmv25759-bib-0056){ref-type="ref"}

Further analyses of HA protein of study strains (Table [1](#jmv25759-tbl-0001){ref-type="table"}) showed amino acid change at position 13 in the signal peptide of HA (A13T), all belonging to clade 1 i.e. (6B.1) while MK246055 (A/Saudi Arabia/86/2015) and MK246063 (A/Saudi Arabia/94/2015) had the I338V amino acid change in the stalk domain which is a characteristic marker for all clades, when compared to the clade 1 viruses.  Amino acid changes were found at key antigenic sites, such as position S101N, S179N (antigenic site‐Sa), I233T (antigenic site‐Sb) in the head domain.  Along with these substitutions, overall sequence diversity in HA was not high for 6B.1. 

3.1.  Selection pressure on A(H1N1)pdm09 {#jmv25759-sec-0130}
---------------------------------------

We assumed that the influenza HA protein is subjected to selection pressure to evade the host cell recognition, the rate of change was assessed by the *ω* values in which *ω* \< 1 meant that negative or purifying selection was present, *ω* = 1 when selection pressure was neutral, and *ω* \> 1 when there was positive selection.[^57^](#jmv25759-bib-0057){ref-type="ref"} The analysis showed that the overall *ω* value of the coding HA1 regions of influenza A(H1N1)pdm09 was 0.23.  Since the majority of residues (N = 42) in the HA1 domain showed *ω* \< 1, this suggested that the amino acids in the HA epitope domain were under purifying selection.  Although overall positive selection was not present, specific sites of positive selection were found using SLAC and FEL methods. 

3.2.  Prediction of glycosylation sites {#jmv25759-sec-0140}
--------------------------------------

The majority of influenza A(H1N1) strains possessed seven potential glycosylation sites in the HA1 domain at amino acid positions 10, 11, 23, 87, 162, 276, and 287, which were present in all but clade 6A. The mutation at N11S among clade 6A strains resulted in a loss of potential glycosylation site at this position.  We did not find the D222G mutation commonly associated with increased virulence.[^58^](#jmv25759-bib-0058){ref-type="ref"}

4.  DISCUSSION {#jmv25759-sec-0150}
=============

Surface proteins of influenza viruses are subjected to a high selective pressure because they have to avoid recognition by the host\'s immune system as well as improve virus fitness by modulating their activity according to the nature of the host.  One of the main mechanisms of variation is antigenic drift, which is the introduction of mutations in known antigenic sites as a response to the recognition by the immune system.  To describe the antigenic drift in the circulating H1N1 viruses from 2014 to 2015 season, we studied genetic diversity along with amino acid changes in HA and NA genes of 80 Saudi isolates.  We found 42 and 14 amino acid changes in HA (Table [1](#jmv25759-tbl-0001){ref-type="table"} and Figure [2](#jmv25759-fig-0002){ref-type="fig"}) and NA (Table [2](#jmv25759-tbl-0002){ref-type="table"}) proteins respectively.  Out of the 42 mutations, 7 substitution sites were located in the HA head domain while only 2 changes were located in the stalk domain (Table [1](#jmv25759-tbl-0001){ref-type="table"}).  Four amino acids were found in previously characterized[^52^](#jmv25759-bib-0052){ref-type="ref"} Ab‐binding sites.  These changes were representative of those found in the HA or NA proteins of circulating viruses during 2014 to 2015 season (Figure [1](#jmv25759-fig-0001){ref-type="fig"}).  These amino acid changes remained present in the HA and NA proteins of the strains isolated during the subsequent season, further suggesting the stability of these changes. 

Recent advancements in the method development have made phylogenetic inference quite important as a promising tool for evaluating the antigenic evolution of influenza viruses from the genetic data.  Unlike the classical Hemagglutination Inhibition assay uses post‐infection animal and/or human antisera, phylogenetic analyses, on the other hand, can exploit easier to generate, and hence more richly available data to achieve high levels of prediction accuracy.[^59^](#jmv25759-bib-0059){ref-type="ref"} Despite good vaccine coverage, infected subjects continue to exhibit low Hemagglutination Inhibition Antibodies (HAI Ab) titers against the vaccine and circulating strains.[^60^](#jmv25759-bib-0060){ref-type="ref"} This suggests that poor responses to the H1N1 component of the vaccine as well as antigenic differences in the HA and NA proteins of currently circulating H1N1 viruses could be contributing to risk of infection even after vaccination. 

After its emergence in 2009 and the following years, circulating influenza H1N1 viruses were closely related to the vaccine strain A/California/07/2009 and mostly characterized by a few amino acid changes.  Based on HA protein, viruses along with their variants emerged from clades 3 and 4 and remained prevalent.  In the first season following 2009 pandemic, H1N1 viruses diverged considerably leading to the formation of several clades with many genetic markers.  During 2011 to 2012 season, six different clades namely 2, 3, 4, 5, 6, and 7 were in circulation throughout the world.  Although, viruses belonging to clade 5 and 7 were few in circulation during that time but emergence and divergence of clade 6 viruses especially into 6b and 6c lead to the replacement of previous 6b strains in 2013 to 2014.[^61^](#jmv25759-bib-0061){ref-type="ref"} During 2015 to 2016 season, clade 6b viruses diverged further into 6b.1 and 6b.2 subclades after the introduction of new amino acid changes.  These subclades remained dominant in Europe, North America but not in Asia, Africa or South America in 2015.  6b.1 became dominant all over the world in 2016[^23^](#jmv25759-bib-0023){ref-type="ref"}, [^29^](#jmv25759-bib-0029){ref-type="ref"} but we found that 6b.1 and 6b.2 were circulating in Saudi Arabia in 2015 (Table [1](#jmv25759-tbl-0001){ref-type="table"}).  The viruses belonging to clade 6b.1 were the most dominant compared to other regions at that time. 

Although the rates of amino acid changes in the HA and NA genes in our study might not be very high than previous seasons[^62^](#jmv25759-bib-0062){ref-type="ref"} the on‐going genetic evolution that had been accumulated in circulating H1N1 strains since the WHO vaccine recommendation made for the season 2017 to 2018 might deepen the antigenic disparity between the vaccine and circulating H1N1 strains in the 2019 to 2020 season.[^63^](#jmv25759-bib-0063){ref-type="ref"} The phylogenetic clustering pattern of the HA and NA genes might substantiate the significance of the rise in influenza cases with regard to the comprehensive process of vaccine virus selection.  The amino acid substitutions in the form of reversion mutations observed especially in the head domain of antigenic sites were quite striking.  For 2019 to 2020, influenza vaccine composition for Northern Hemisphere was recommended by WHO.[^64^](#jmv25759-bib-0064){ref-type="ref"} Food and Drug Administration (FDA) along with Vaccines and Related Biologic Products Advisory Committee make the influenza vaccine composition recommendation in the United States of America (USA).[^45^](#jmv25759-bib-0045){ref-type="ref"}, [^65^](#jmv25759-bib-0065){ref-type="ref"} Both agencies recommend that influenza trivalent vaccines contain an A/Brisbane/02/2018 A(H1N1)pdm09‐like virus, an A/Kansas/14/2017 A(H3N2)‐like virus, and a B/Colorado/06/2017‐like (B/Victoria lineage) virus.  The recommendation for quadrivalent vaccine included the trivalent vaccine viruses and a B/Phuket/3073/2013‐like (B/Yamagata lineage) virus.  The A(H1N1)pdm09 and A(H3N2) recommendations are an update to the 2018‐2019 Northern Hemisphere vaccines.  The A(H1N1)pdm09 component has been updated keeping in view of genetic and antigenic characterization data showing significantly reduced titers (eight‐fold or greater) to recent 6B.1A viruses, compared with the titers against the A/Michigan/45/2015 vaccine virus.[^66^](#jmv25759-bib-0066){ref-type="ref"}, [^67^](#jmv25759-bib-0067){ref-type="ref"}, [^68^](#jmv25759-bib-0068){ref-type="ref"}

Most of the protective antibodies induced by vaccination or infection with influenza virus are specific to the HA protein.[^69^](#jmv25759-bib-0069){ref-type="ref"}, [^70^](#jmv25759-bib-0070){ref-type="ref"} As a result, most studies focus mainly on the antigenicity of the HA protein.  However, protective antibodies specific to the NA protein are also elicited in animal models and humans,[^71^](#jmv25759-bib-0071){ref-type="ref"}, [^73^](#jmv25759-bib-0073){ref-type="ref"} and antigenic drift in the NA has been reported to occur.[^74^](#jmv25759-bib-0074){ref-type="ref"}, [^75^](#jmv25759-bib-0075){ref-type="ref"} There were 14 mutations in the NA protein encoded by Saudi viruses circulating during the 2014‐15 season when compared to the vaccine strain, 4 of which were located in previously identified antigenic sites (Table [2](#jmv25759-tbl-0002){ref-type="table"}).[^53^](#jmv25759-bib-0053){ref-type="ref"} If the NAI Ab titers for the circulating strains are low than for the vaccine strain, it might suggest that there is antigenic variability in the NA protein expressed by currently circulating viruses.  This, in turn, could lead to a decrease in the efficacy of the vaccine.  These antigenic differences could be due to the amino acid changes in defined Ab binding sites (N200S, N248D, N369K, and K432E).[^53^](#jmv25759-bib-0053){ref-type="ref"} Alternatively, due to the poor understanding of the antigenicity of the NA protein, some other amino acid changes might also affect the Ab binding. 

Amino acid changes at key antigenic sites in our study, such as position N179S, Q180T (antigenic site‐Sa), S200P, T202N (antigenic site‐Sb) along with N101S, N114S, and T233I in the head domain might have resulted in antigenic drift and emergence of variant viruses.  H1 gene sequences in comparison to 2010‐2016 vaccine strain recently in India have shown mutations K166Q and S188T resulting in the emergence of variants.[^76^](#jmv25759-bib-0076){ref-type="ref"} Amino acid substitutions other than at position 166 in major antigenic site Sa can be selected by the immunological pressure of antibodies, that recognize an epitope including position 166.  In combination with computational analyses and other methods,[^77^](#jmv25759-bib-0077){ref-type="ref"} in vitro selection of potential antigenic drift mutants could improve the selection of vaccine seed viruses.[^78^](#jmv25759-bib-0078){ref-type="ref"} Viral protein‐host interactions that are lost with the mutation are compensated by interactions with other amino acids, leading to a more stable HA.[^79^](#jmv25759-bib-0079){ref-type="ref"} The HA from influenza A(H1N1)pdm09 virus is steadily evolving towards a more stable and antigenically distinct protein.  This trend indicates that current influenza vaccines are likely to have a decreased efficacy if the same strain is used in future vaccine formulations. 

5.  CONCLUSIONS {#jmv25759-sec-0160}
==============

Between the years of antigenic shift, the variable extent and severity of influenza outbreaks are due to antigenic drift.  Therefore, HA and NA complete gene sequencing data in this study provides a closer look into the epidemiological pattern of circulating influenza A (H1N1) viruses and the antigenic mismatches between circulating and vaccine strains.  The potential amino acid changes responsible for antigenic drift found in this study would help further to measure the impact that influenza is having on hospitalizations and deaths in Saudi Arabia.  These findings will direct further research for further vaccine effectiveness studies to aid in proper treatment options to reduce hospitalization due to these infections. 

CONFLICT OF INTERESTS {#jmv25759-sec-0180}
=====================

The authors declare that there are no conflict of interests. 

AUTHOR CONTRIBUTIONS {#jmv25759-sec-0190}
====================

AN: study design, experimental work, data collection and analysis, manuscript writing and review.  KE: reviewed the experimental data, analyses and manuscript.  BA: study design, data analysis, results discussion, manuscript review.  AA: performed homology structural analysis of proteins.  HA: data analysis, results discussion, manuscript review.  SA: database work‐up and data collection.  ME: results discussion, manuscript review.  All authors read and approved the final manuscript. 

ETHICS STATEMENT {#jmv25759-sec-0220}
================

All procedures performed in this study involving clinical specimen were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.  The study was approved by the Institutional Review Board at King Fahad Medical City (IRB Log No.  16‐266).  Informed consent to participate was waived or not required since only remaining left‐over specimens were used for this study. 

The authors thank Dr Fatimah S Alhamlan and Lama Abdullah for their excellent technical support.  They also thank KFMC diagnostic Laboratories and for their contribution in sample collection.  This study was supported by the Intra‐mural Research Fund (IRF) from the King Fahad Medical City for funding this study (Grant No 017‐024). 

DATA AVAILABILITY STATEMENT {#jmv25759-sec-0210}
===========================

The clinical datasets used and/or analyzed during the current study are available from the corresponding author on request.